Xencor Inc. (XNCR) 14.48 $XNCR
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 14.48 (-0.18)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 14.48 (-0.18)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 14.48 (-0.18)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 14.48 (-0.18)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 3.27 (-0.13), XNCR: 14.48 (-0.18)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 154.78 (-2.00), XNCR: 14.48 (-0.18)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 14.48 (-0.18)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.84 (-0.38), XNCR: 14.48 (-0.18), PDLI: 3.15 (-0.12)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 14.48 (-0.18)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 14.48 (-0.18)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 14.48 (-0.18)
National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
PR Newswire - Thu Jan 07, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that the National Institutes of Health (NIH) has initiated a Phase 1 clinical trial of VRC01LS, a therapeutic antibody for the treatment of HIV that uses Xencor's Xtend antibody half-life extension technology.
XNCR: 14.48 (-0.18)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.68 (-0.03), TSRO: 40.34 (-1.48), CTMX: 10.17 (+0.13), NK: 6.70 (-0.37), CNCR: 23.11 (-0.64), SRNE: 6.34 (-0.10), XNCR: 14.48 (-0.18), ONTY: 1.21 (+0.02), CYAD: 49.75 (-1.25)
Equities Lead Investor Sentiment - Research Reports on TriNet Group, Xencor, Keryx Biopharmaceuticals and TeleCommunication Systems
ACCESSWIRE - Fri Dec 11, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: TriNet Group Inc (NYSE: TNET), Xencor Inc (NASDAQ: XNCR), Keryx Biopharmaceuticals (NASDAQ: KERX) and TeleCommunication Systems, Inc. (NASDAQ: TSYS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TSYS: 4.99 (-0.02), XNCR: 14.48 (-0.18), TNET: 20.10 (-0.21), KERX: 5.93 (-0.12)
Global & USA BioSimilar Market Report - Analysis, Trends, Technologies & Opportunities to 2021
M2 - Mon Dec 07, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/874kl9/global_and_usa) has announced the addition of the "Global & USA BioSimilar Market Analysis to 2021" report to their offering. This report provides a comprehensive overview of the size of biosimilars' market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. The report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen's Neupogen) in March 2015 is to transform the otherwise nascent market. Key Topics: - The Market Potential for Biosimilars in the U.S. - Projected U.S. Biosimilar Market, Through 2020 - Optimistic Predictions for the Growth of Biosimilars' Market in the U.S. - Timeline for U.S. Patent Expiration of Branded Biologics - Viability of Biosimilars in the U.S. - Cost of Developing and Bringing a Biosimilar into the U.S. Market - Projected Savings with Biosimilars in the U.S. - Projected Savings with Biosimilars of 11 Specific Biologics in the U.S., 2012-2024 - Multiple Challenges for Biosimilars' Entry into the U.S. Market - Break-Even Analysis for Biosimilars in the U.S. - Biosimilars About to Enter the U.S. Market - Top Five Players Focused on Developing Biosimilars for the U.S. Market Companies Mentioned Include: - 3SBio - AET BioTech - Abzena - Actavis - Avesthagen Ltd. - Baxter International Inc. - Pfizer Inc. - Synthon BV - Teva Pharmaceutical Industries Ltd. - USV Ltd. - Wockhardt Ltd. - Xencor Inc. - Xiamen Amoytop Biotech Co., Ltd. - mAbxience Report Structure: 1.0 Introduction 2.0 Biosimilars: A Brief Overview 3.0 Regulations for Biosimilars: An Overview 4.0 Development of Biosimilars: An Overview 5.0 Biobetters: An Overview 7.0 The Impact of Biosimilars on Originators: An overview 8.0 Top Ten Biologics on the Focus of Biosimilar Developers 9.0 Five Major Classes of Originator Biologics and their Market Performance 10.0 The Landscape of the Originators of Biosimilars 11.0 A Brief Analysis of Market for Biologics 12.0 Market for Biosimilars: An Overview 13.0 Selected Company Profiles 14.0 Biosimilar Market Participants and their Focused Products For more information visit http://www.researchandmarkets.com/research/87...al_and_usa
BAX: 44.49 (-0.26), PFE: 35.29 (-0.02), TEVA: 53.01 (-0.30), XNCR: 14.48 (-0.18)
Xencor to Present at Two Upcoming Conferences in December
PR Newswire - Tue Nov 24, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at two upcoming conferences in December:
XNCR: 14.48 (-0.18)
Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting
PR Newswire - Mon Nov 09, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA) are being presented during an oral presentation today, Monday, November 9, 2015 at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, California. Complete data results on the Phase 1b/2a RA study were previously announced at the European League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome in June 2015.
XNCR: 14.48 (-0.18)
Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting
PR Newswire - Thu Nov 05, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that a preclinical study of Xencor's bispecific CD38xCD3 program will be featured in a presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in December. The preclinical data support further development of Xencor's CD38xCD3 bispecific antibodies in multiple myeloma and other CD38+ malignancies.
XNCR: 14.48 (-0.18)
Global Market Study on Next-Generation Antibody Therapeutics 2015: Biosimilar Antibody Products to Witness Highest Growth by 2022
M2 - Thu Nov 05, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/zq8pjv/global_market) has announced the addition of the "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022" report to their offering. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022. Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. North America is the largest market for next-generation antibody therapeutics. In terms of technology, antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics market. On the basis of therapeutic application, oncology dominates the next-generation antibody therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the increasing use of ADC technology. Various biotechnology and biopharmaceutical companies are actively involved in development and manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs Chapter 6 Global Market Size and Forecast Chapter 7 Market Size and Forecast by Therapeutic Area Chapter 8 Market Size and Forecast by Technology Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - Amgen, Inc. - AstraZeneca - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen, Inc. - Kyowa Hakko Kirin Co., Ltd. - Pfizer, Inc. - Seattle Genetics, Inc. - Takeda Pharmaceuticals Company Limited - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/zq...bal_market
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 14.48 (-0.18)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 14.48 (-0.18)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 14.48 (-0.18)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 14.48 (-0.18)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 3.27 (-0.13), XNCR: 14.48 (-0.18)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 154.78 (-2.00), XNCR: 14.48 (-0.18)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 14.48 (-0.18)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.84 (-0.38), XNCR: 14.48 (-0.18), PDLI: 3.15 (-0.12)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 14.48 (-0.18)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 14.48 (-0.18)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 14.48 (-0.18)
National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
PR Newswire - Thu Jan 07, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that the National Institutes of Health (NIH) has initiated a Phase 1 clinical trial of VRC01LS, a therapeutic antibody for the treatment of HIV that uses Xencor's Xtend antibody half-life extension technology.
XNCR: 14.48 (-0.18)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.68 (-0.03), TSRO: 40.34 (-1.48), CTMX: 10.17 (+0.13), NK: 6.70 (-0.37), CNCR: 23.11 (-0.64), SRNE: 6.34 (-0.10), XNCR: 14.48 (-0.18), ONTY: 1.21 (+0.02), CYAD: 49.75 (-1.25)
Equities Lead Investor Sentiment - Research Reports on TriNet Group, Xencor, Keryx Biopharmaceuticals and TeleCommunication Systems
ACCESSWIRE - Fri Dec 11, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: TriNet Group Inc (NYSE: TNET), Xencor Inc (NASDAQ: XNCR), Keryx Biopharmaceuticals (NASDAQ: KERX) and TeleCommunication Systems, Inc. (NASDAQ: TSYS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TSYS: 4.99 (-0.02), XNCR: 14.48 (-0.18), TNET: 20.10 (-0.21), KERX: 5.93 (-0.12)
Global & USA BioSimilar Market Report - Analysis, Trends, Technologies & Opportunities to 2021
M2 - Mon Dec 07, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/874kl9/global_and_usa) has announced the addition of the "Global & USA BioSimilar Market Analysis to 2021" report to their offering. This report provides a comprehensive overview of the size of biosimilars' market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. The report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen's Neupogen) in March 2015 is to transform the otherwise nascent market. Key Topics: - The Market Potential for Biosimilars in the U.S. - Projected U.S. Biosimilar Market, Through 2020 - Optimistic Predictions for the Growth of Biosimilars' Market in the U.S. - Timeline for U.S. Patent Expiration of Branded Biologics - Viability of Biosimilars in the U.S. - Cost of Developing and Bringing a Biosimilar into the U.S. Market - Projected Savings with Biosimilars in the U.S. - Projected Savings with Biosimilars of 11 Specific Biologics in the U.S., 2012-2024 - Multiple Challenges for Biosimilars' Entry into the U.S. Market - Break-Even Analysis for Biosimilars in the U.S. - Biosimilars About to Enter the U.S. Market - Top Five Players Focused on Developing Biosimilars for the U.S. Market Companies Mentioned Include: - 3SBio - AET BioTech - Abzena - Actavis - Avesthagen Ltd. - Baxter International Inc. - Pfizer Inc. - Synthon BV - Teva Pharmaceutical Industries Ltd. - USV Ltd. - Wockhardt Ltd. - Xencor Inc. - Xiamen Amoytop Biotech Co., Ltd. - mAbxience Report Structure: 1.0 Introduction 2.0 Biosimilars: A Brief Overview 3.0 Regulations for Biosimilars: An Overview 4.0 Development of Biosimilars: An Overview 5.0 Biobetters: An Overview 7.0 The Impact of Biosimilars on Originators: An overview 8.0 Top Ten Biologics on the Focus of Biosimilar Developers 9.0 Five Major Classes of Originator Biologics and their Market Performance 10.0 The Landscape of the Originators of Biosimilars 11.0 A Brief Analysis of Market for Biologics 12.0 Market for Biosimilars: An Overview 13.0 Selected Company Profiles 14.0 Biosimilar Market Participants and their Focused Products For more information visit http://www.researchandmarkets.com/research/87...al_and_usa
BAX: 44.49 (-0.26), PFE: 35.29 (-0.02), TEVA: 53.01 (-0.30), XNCR: 14.48 (-0.18)
Xencor to Present at Two Upcoming Conferences in December
PR Newswire - Tue Nov 24, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at two upcoming conferences in December:
XNCR: 14.48 (-0.18)
Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting
PR Newswire - Mon Nov 09, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA) are being presented during an oral presentation today, Monday, November 9, 2015 at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, California. Complete data results on the Phase 1b/2a RA study were previously announced at the European League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome in June 2015.
XNCR: 14.48 (-0.18)
Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting
PR Newswire - Thu Nov 05, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that a preclinical study of Xencor's bispecific CD38xCD3 program will be featured in a presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in December. The preclinical data support further development of Xencor's CD38xCD3 bispecific antibodies in multiple myeloma and other CD38+ malignancies.
XNCR: 14.48 (-0.18)
Global Market Study on Next-Generation Antibody Therapeutics 2015: Biosimilar Antibody Products to Witness Highest Growth by 2022
M2 - Thu Nov 05, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/zq8pjv/global_market) has announced the addition of the "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022" report to their offering. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022. Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. North America is the largest market for next-generation antibody therapeutics. In terms of technology, antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics market. On the basis of therapeutic application, oncology dominates the next-generation antibody therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the increasing use of ADC technology. Various biotechnology and biopharmaceutical companies are actively involved in development and manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs Chapter 6 Global Market Size and Forecast Chapter 7 Market Size and Forecast by Therapeutic Area Chapter 8 Market Size and Forecast by Technology Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - Amgen, Inc. - AstraZeneca - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen, Inc. - Kyowa Hakko Kirin Co., Ltd. - Pfizer, Inc. - Seattle Genetics, Inc. - Takeda Pharmaceuticals Company Limited - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/zq...bal_market
SGEN: 40.38 (-0.63), PFE: 35.29 (-0.02), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), XNCR: 14.48 (-0.18), DYAX: 38.04 (-0.37)
